Key Takeaways for Regeneron Pharmaceuticals Stock as of August 2026
- Across-the-Board Beat: Regeneron posted Q2 2026 revenue of $4.29B against a $3.82B Street estimate, a 12.22% beat that also marked 16.73% YoY growth and 19.01% QoQ growth.
- Margin Expansion: EBIT hit $1.65B versus a $1.19B estimate, a 39.35% beat, pushing EBIT margins to 38.53% and topping Street’s 31.03% forecast by 750 basis points.
- Sanofi Debt Payoff: CFO Chris Fenimore confirmed Regeneron fully repaid its Sanofi development balance in Q2, and said collaboration revenue will “step up” starting Q3 as the company records its full share of Dupixent profits.
- Cash Flow Surge: Cash flow from operations came in at $813.00M against a $197.83M estimate, a 310.96% beat, even as CFO fell 28.96% YoY and 24.65% QoQ against tougher prior comparisons.
Dupixent’s 38% Growth and a Sanofi Payoff Reset REGN Stock’s Trajectory
Regeneron (REGN) delivered a second quarter that outran Wall Street on every reported line, with revenue of $4.29 billion against a Street estimate of $3.82 billion, a beat of 12.22% and growth of 16.73% year over year. Adjusted EPS reached $14.29 versus an estimated $10.21, a 39.99% beat and the company’s second straight quarter of double-digit growth on both revenue and earnings. Regeneron stock closed at $762.63 on July 31, up 3.29% on the day.
The engine behind the quarter was Dupixent, the eczema and asthma drug Regeneron co-develops with Sanofi. Global net product sales reached $6.0 billion, up 38% on a constant currency basis, with demand strong across all nine approved indications. That growth flowed directly into Regeneron’s collaboration economics: total Sanofi collaboration revenue hit an all-time high of $2.2 billion, and Regeneron’s share of collaboration profits grew 59% year over year. CFO Chris Fenimore explained why that growth rate is about to change shape.
On the Q2 earnings call, he said Regeneron “fully repaid the Sanofi development balance, which was approximately $3.1 billion when the Sanofi antibody collaboration agreement was amended,” adding that “given full repayment of the Sanofi development balance starting in the third quarter, we expect Sanofi collaboration revenue to step up as we record our full share of collaboration profits.” That repayment had suppressed reported collaboration revenue by roughly $930 million in 2025 and $530 million in the first half of this year, so its removal is a structural, not cyclical, tailwind.
EYLEA HD, Regeneron’s next-generation eye drug, kept converting share from the older EYLEA. U.S. net sales hit $596 million, up 52% year over year, and for the first time outsold EYLEA outright as EYLEA’s own U.S. sales fell 45% to $412 million. Libtayo added $489 million worldwide, up 29% on a constant currency basis, with its share of new-to-brand lung cancer prescriptions in the U.S. doubling to 20% since early 2025.
Profitability followed the top line higher. EBIT margins expanded 750 basis points above the Street’s estimate to 38.53%, while non-GAAP gross margin held at 87% even as GAAP gross margin absorbed a temporary manufacturing disruption at Regeneron’s Limerick, Ireland facility, now resolved as of quarter-end. Regeneron ended the quarter with $15.1 billion in cash and marketable securities net of debt and repurchased $1.2 billion of stock in the quarter alone.
TIKR Values REGN Stock at $1,074, Pointing to 41% Total Return by 2030
TIKR’s mid-case model values Regeneron at $1,074 by the end of 2030, implying a 41% total return from the current price of $763, or 8% annualized over the next 4.4 years.
That return profile places Regeneron stock closer to a steady compounder than a re-rating story, with the model leaning on earnings growth rather than a stretched multiple to close the gap to target. The TIKR model’s mid case assumes 6.9% revenue growth and 39% net income margins through the forecast window, both consistent with a business already running above those marks in the quarter just reported.
That assumption set lines up with what the quarter delivered. EBIT margins of 38.53% already sit near the model’s mid-case net margin target, and with the Sanofi development balance now retired, the model’s revenue growth assumption looks conservative next to a collaboration segment about to record its full profit share for the first time in years.
Dupixent’s 38% constant currency growth and EYLEA HD’s continued conversion from EYLEA give the model’s mid case a reasonable floor to build from into 2030.
Should You Invest in Regeneron Pharmaceuticals, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Regeneron Pharmaceuticals, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Regeneron Pharmaceuticals, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze REGN stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
